Drugs / Afuresertib
Afuresertib
Trials 19 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 110 trials | ||||||
| Phase 1 | NCT05489744 | Aug → Oct 2022 | — | Laekna Limited | Completed | No outcome recorded |
| Phase 1 | NCT05390710 | Jun 2021 → Dec 2023 | triple-negative breast carcinoma | Laekna Limited | Completed | No outcome recorded |
| Phase 1 | NCT02380313 | Oct 2015 → May 2017 | cancer | GlaxoSmithKline | Withdrawn | No outcome recorded |
| Phase 1 | NCT02235740 | Nov 2014 → Oct 2015 | cancer | Novartis | Terminated | No outcome recorded |
| Phase 1 | NCT02240212 | Oct 2014 → Feb 2017 | cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02177682 | Aug 2014 → Feb 2017 | hematopoietic and lymphoid system neoplasm | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT02040480 | Feb → Apr 2014 | cancer | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01827644 | Apr → Jul 2013 | cancer | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01428492 | Dec 2011 → Oct 2015 | plasma cell myeloma | Novartis | Completed | No outcome recorded |
| Phase 1 | NCT01476137 | Oct 2011 → Mar 2013 | cancer | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT05383482 | Jul 2022 → Jun 2024 | cervical cancer, endometrial cancer, esophageal cancer, gastroesophageal adenocarcinoma +1 | Laekna Limited | Completed | No outcome recorded |
| Phase 1/2 | NCT04060394 | Sep 2019 → Dec 2023 | castration-resistant prostate carcinoma | Laekna Limited | Completed | No outcome recorded |
| Phase 1/2 | NCT01653912 | Nov 2012 → Jul 2015 | — | Accenture | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT04374630 | Jun 2020 → Jul 2023 | refractory malignant neoplasm | Laekna Limited | Completed | No outcome recorded |
| Phase 2 | NCT01531894 | Feb 2012 → Jun 2018 | cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01532700 | Feb 2012 → Jun 2017 | B-cell chronic lymphocytic leukemia | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 2 | NCT01445587 | Nov 2011 | cancer | GlaxoSmithKline | Withdrawn | No outcome recorded |
| Phase 2 | NCT01395004 | Nov 2011 → Nov 2013 | Langerhans cell histiocytosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04851613 | Feb 2022 → Oct 2026 expected | breast cancer | Laekna Limited | Active not recruiting | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | afuresertib | “GSK2110183 (afuresertib)” NCT01531894 ↗ |
| Known as | AFU | “of afuresertib (AFU), in the fed and fasted state” NCT01827644 ↗ |
| Known as | AFURESERTIB HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2219422 ↗ |
| Known as | ASB-183 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2219422 ↗ |
| Known as | GSK-2110183B | ChEMBL registry synonym — accepted as the source's own label CHEMBL2219422 ↗ |
| Known as | GSK-2110183C | ChEMBL registry synonym — accepted as the source's own label CHEMBL2219422 ↗ |
| Known as | GSK2110183 | “receive a single oral dose of 125mg GSK2110183” NCT01445587 ↗7“Afuresertib (GSK2110183)” NCT02040480 ↗ |
| Action | Inhibit | “Oral AKT Inhibitor GSK2110183” NCT01395004 ↗ |
| Modality | Small molecule | “Oral AKT Inhibitor GSK2110183” NCT01395004 ↗ |
| Route | Oral | “GSK2110183 was orally administered at 125 mg once daily.” NCT01395004 ↗ |